e-learning resources

ERS International Congress, Milan 2017

Browse by day: Saturday, 09.09.2017 Sunday, 10.09.2017 Monday, 11.09.2017 Tuesday, 12.09.2017 Wednesday, 13.09.2017		Sponsored symposia: Industry Evening Symposium at ERS 2017: “Evolving Concepts in Asthma with Type 2 Inflammation: the Role of Biologics”

Citations should be made in the following way: Authors. Title. Eur Respir J 2017; 50: Suppl. 61, abstract number.

Outcomes and new treatment strategies in pulmonary hypertension

Poster Discussion
Chairs: M. Humbert (Paris, France), R. De Souza (Sao Paulo/Sp, Brazil)

Download all media

Download all media

Late Breaking Abstract - Long-term outcome of perioperative extracorporeal membrane oxygenation (ECMO) in patients undergoing pulmonary endarterectomy (PEA). E. Swietlik (Warszawa, Poland)
Is there an obesity paradox in pulmonary arterial hypertension? J. Weatherald (Calgary, AB, Canada)
Hispanic patients with pulmonary arterial hypertension: Preliminary results from a contemporary national registry J. Gomez-Arroyo (Cincinatti, United States of America)
Supraventricular Arrhythmias in Pulmonary Arterial Hypertension V. Mercurio (Baltimore, United States of America)
Effect of targeted therapies on survival of schistosomiasis associated pulmonary arterial hypertension B. Mamprim Piloto (SAO PAULO/SP, Brazil)
Clinical phenotypes and outcomes of pulmonary hypertension due to left heart disease: role of the pre-capillary component S. Caravita (Milano, MI, Italy)
Outcomes of patients with precapillary pulmonary hypertension admitted to an intensive care unit for acute right heart failure. L. Savale (Le Kremlin Bicêtre, France)
Risk categories from European guidelines applied to the French Pulmonary Hypertension (PH) registry A. Boucly (PARIS, France)
Multi-step therapy with riociguat, balloon pulmonary angioplasty, and cardiac rehabilitation for inoperable chronic thromboembolic pulmonary hypertension S. Fukui (Osaka, Japan)
Poor Subpleural Perfusion as a predictor of Failure after Balloon Pulmonary Angioplasty for non-operable Chronic Thromboembolic Pulmonary Hypertension Y. Taniguchi (Paris, France)
Audit of disease targeted therapies in adult patients with pulmonary arterial hypertension W. Gin-Sing (London, United Kingdom)
Effect of long-term oxygen therapy on exercise capacity and quality of life in exercise-desaturating patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomized-sham-controlled cross-over trial S. Ulrich (Zurich, Switzerland)
Initial combination of macitentan and tadalafil in newly diagnosed patients with pulmonary arterial hypertension (PAH): results from the OPTIMA study O. Sitbon (Le Kremlin-Bicêtre, France)
Safety and efficacy of immunoadsorption as an add-on to medical treatment in patients with idiopathic pulmonary arterial hypertension B. Egenlauf (Heidelberg, Germany)
Safety of riociguat for the treatment of pulmonary hypertension: Data from the EXPERT registry H. Gall (Giessen, Germany)
Transitioning pulmonary arterial hypertension patients from bosentan to macitentan: efficacy and safety data. M. Santos (Porto, Portugal)
Prognostic impact of exercise pulmonary hypertension R. Oliveira (SAO PAULO/SP, Brazil)

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.